{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:12:10Z","timestamp":1784344330315,"version":"3.55.0"},"reference-count":42,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BioMed Research International"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:p>We compared the cost-utility analysis for edoxaban at both doses with that of dabigatran at both doses, rivaroxaban, and apixaban (non vitamin K antagonist oral anticoagulants, NOAC) in a German population. Data of clinical outcome events were taken from edoxaban\u2019s ENGAGE-AF, dabigatran\u2019s RE-LY, rivaroxaban\u2019s ROCKET, and apixaban\u2019s ARISTOTLE trials. The base-case analyses of a 65-year-old person with a CHADS2 score &gt;1 gained 0.17 and 0.21 quality-adjusted life years over warfarin for 30\u2009mg\u2009od and 60\u2009mg\u2009od edoxaban, respectively. The incremental cost-effectiveness ratio was 50.000 and 68.000 euro per quality-adjusted life years for the higher and lower dose of edoxaban (Monte Carlo simulation). These findings were also similar to those for apixaban and more cost-effective than the other NOAC regimens. The current market costs for direct oral anticoagulants are high in relation to the quality of life gained from a German public health care insurance perspective. The willingness-to-pay threshold was lowest for 60\u2009mg edoxaban compared to all direct oral anticoagulants and for 30\u2009mg edoxaban compared to dabigatran and rivaroxaban.<\/jats:p>","DOI":"10.1155\/2015\/876923","type":"journal-article","created":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T18:39:01Z","timestamp":1426617541000},"page":"1-12","source":"Crossref","is-referenced-by-count":18,"title":["Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany"],"prefix":"10.1155","volume":"2015","author":[{"given":"Martin","family":"Krejczy","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Maybachstra\u00dfe 14, 68169 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job","family":"Harenberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Maybachstra\u00dfe 14, 68169 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wehling","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Maybachstra\u00dfe 14, 68169 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0687-5014","authenticated-orcid":true,"given":"Konrad","family":"Obermann","sequence":"additional","affiliation":[{"name":"Mannheim Institute of Public Health, Medical Faculty Mannheim, Ludolf-Krehl Stra\u00dfe, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Sciences, City Hospital, University of Birmingham, Birmingham B187QH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-013-0989-6"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00489.x"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs204"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2293"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.276.15.1253"},{"key":"10","year":"2009"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp318"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-1-201101040-00289"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.985655"},{"key":"15","year":"2005"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.156.16.1829"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00663.x"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.6.699"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9301300202"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1177\/0272989x06290495"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200321030-00004"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)90012-6"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-009-3189-6"},{"key":"24","year":"2006"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-963505"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-11-0758"},{"key":"27","first-page":"421","volume-title":"Antithrombotika und Antih\u00e4morrhagika","year":"2011"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-02-0089"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6333"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2011-300646"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.673525"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs157"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1016\/j.repc.2013.01.005"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.05.011"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.000402"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.01.009"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-013-0144-3"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-06-0388"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0035-8"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22112"},{"issue":"4","key":"41","first-page":"330","volume":"31","year":"2012","journal-title":"International Angiology"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062183"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1007\/s00063-008-1122-z"}],"container-title":["BioMed Research International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2015\/876923.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2015\/876923.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2015\/876923.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T21:16:56Z","timestamp":1471555016000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.hindawi.com\/journals\/bmri\/2015\/876923\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":42,"alternative-id":["876923","876923"],"URL":"https:\/\/doi.org\/10.1155\/2015\/876923","relation":{},"ISSN":["2314-6133","2314-6141"],"issn-type":[{"value":"2314-6133","type":"print"},{"value":"2314-6141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}